Navigation Links
Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
Date:6/27/2011

six month priority review by the FDA. In the U.S., XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma.(iv)  XGEVA is also approved in Canada for reducing the risk of developing SREs in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors.  In Canada, XGEVA is not indicated for reducing the risk of developing SREs in patients with multiple myeloma.

Amgen has also submitted marketing applications for XGEVA in Australia, Mexico, Russia, Switzerland and the European Union. In Japan, Amgen is working with its licensing partner, Daiichi Sankyo Company, Limited and a marketing application was submitted in August. In addition, Amgen and GlaxoSmithKline (GSK) have a collaboration agreement for the commercialization of XGEVA in a number of countries where Amgen does not currently have a commercial presence. In these countries, marketing applications are filed by GSK.

For more information on XGEVA, please visit www.XGEVA.com.

Denosumab is also marketed as Prolia® in other indications.

XGEVA Important Safety Information

XGEVA can cause severe hypocalcemia. Correct pre-existing hypocalcemia prior to XGEVA treatment. Monitor calcium levels and administer calcium, magnesium, and vitamin D as necessary. Advise patients to contact a healthcare professional for symptoms of hypocalcemia.

ONJ can occur in patients receiving XGEVA. Patients who are suspected of having or who develop ONJ while on XGEVA should receive care by a dentist or an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  

The most common adverse reactions in patients receiving XGEVA were fatigue/asthenia, hypophosphatemia, and nausea. The most common serious adverse reaction in patients receiving XGEVA was dyspnea. The most common adverse reactions
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
(Date:9/18/2014)... Washington, D.C. (PRWEB) September 18, 2014 ... Dick Durbin and Sen. Jim Risch for National Lab ... research projects from across the national laboratory system. Durbin ... Caucus, which aims to increase awareness of the reach ... breakthrough technologies and discoveries to address some of our ...
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... 2014 Research and Markets has ... (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends ... The global companion diagnostics market is ... 2014 to 2019. Factors such as rising need for ... diagnostics by the pharmaceutical industry, support from regulatory authorities, ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... CRANBURY, N.J., Sept. 12 Amicus Therapeutics,(Nasdaq: FOLD ... Officer, will present a corporate update at the Merrill ... United,Kingdom on Tuesday, September 18th at 4:00 pm BDT ... A live audio web cast of the presentation will ...
... MORRISVILLE, N.C., Sept. 12 AVOS Life Sciences,announced ... Vice President. His,primary responsibility will be providing advisory ... areas as well as selected investment,assignments in capital ... he will also have responsibility for AVOS, emerging ...
... Robotic-Assisted Coronary ... Artery Bypass Surgery, REDWOOD CITY, Calif., ... it has received European CE Mark,(Conformite Europeenne) approval for the C-Port(R) ... of Cardica,s C-Port(R) xA,Distal Anastomosis System product line and further facilitates ...
Cached Biology Technology:Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 3Senior Research Analyst Richard Evans Joins AVOS Life Sciences 2Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery 2Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery 3
(Date:9/18/2014)... Americans across racial and ethnic groups describe losing ... their day-to-day life, more so than other conditions ... (57% of African-Americans, 49% of non-Hispanic whites, 43% ... which disease or ailment is the worst that ... African-Americans followed by AIDS/HIV. Hispanics and Asians ...
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... too stressed they are often grouchy, grumpy, nasty, distracted ... at EPFL have just highlighted a fundamental synaptic mechanism ... loss of social skills and cognitive impairment. When triggered ... in the brain. This was revealed by a work ... Sandi,s team went to look for answers in a ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Tropical fish a threat to Mediterranean Sea ecosystems 2How stress tears us apart 2
... last couple decades have seen a virtual renaissance of ... functional magnetic resonance imaging (fMRI). Thanks to a ... scholars at Rutgers University will have the latest fMRI ... NSF has awarded Rutgers University in Newark a $1,820,000 ...
... natural organic pesticide for hundreds of years, is getting new ... pesticides. That,s the topic of a report in ACS, bi-weekly ... Cedric Briens and colleagues note that concerns about the health ... in some parts of the world. Scientists are looking for ...
... geoscientist Dr Veerle Huvenne of the United Kingdom,s National Oceanography ... 1.4 million Euros over five years to map complex habitats ... The European Research Council (ERC) ,Starting Grant, scheme aims ... their own research groups. The grants are highly competitive, and ...
Cached Biology News:$1,820,000 from NSF awarded to Rutgers-Newark to acquire fMRI dedicated to research 2
... Ascent is the first nephelometer ... microplates. Nepheloskan measures light scattering ... for particle quantification. This makes ... in drug discovery, immunoprecipitation, and ...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
... Rotarods are used to assess the effect of ... on mice and rats using one unit in ... the animals are placed on textured drums to ... individual sensing platforms below, its test results are ...
Biology Products: